Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of June 2019, with a specific reporting date of June 12, 2019. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £15.8480 per share for all reported transactions.
- Transaction Volume: Ranged from 14 to 16 shares per individual transaction.
- Transaction Date: June 11, 2019.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine compliance disclosures for executive share acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity compliant with market rules.
Important Facts for Investors
- Executive Participation: Multiple senior executives, including CEO Emma Walmsley, acquired shares on the same day (June 11, 2019).
- Transaction Nature: All acquisitions were made under the Company's Share Reward Plan, involving both partnership and matching shares.
- Scale of Transactions: The volume of shares purchased by each individual was minimal (14 to 16 shares), indicating these are likely vesting events or small-scale plan contributions rather than significant open-market purchases.
- Price Consistency: All transactions executed at the identical price of £15.8480.